![](https://static.wixstatic.com/media/b1df9d0901924c1cb6211eaaacf749fc.png/v1/fill/w_96,h_72,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/b1df9d0901924c1cb6211eaaacf749fc.png)
SELENTUS DEVELOPS MEDICAL DEVICES FOR SURGICAL BLEEDING AND WOUND THERAPY
Approved for sale in Europe
Haemostatic absorbable gelatine sponge with surface modification for increased tissue adhesion
![tenataclogo.png](https://static.wixstatic.com/media/d29f85_7ec0c9245ab842838c3ef0fb854b5c15~mv2.png/v1/fill/w_260,h_74,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/tenataclogo.png)
Patents granted in U.K. (GB 2543307), U.S.A (US 10,653,821), Europe (EP 3362110), Japan (JP 6854825), India (497548), Brazil (BR 112018007612-0 B1) and China (CN 108136080 B) and pending in South Korea.
Selentus develops innovative haemostatic technologies for better surgical outcomes. Selentus is developing a pipeline of products based on its unique technology platform that offer high performance, low cost manufacture and avoid the use of blood-derived materials. Selentus' lead product, TenaTac®, was approved for sale in Europe in September 2019 and is licensed to CuraMedrix B.V. in Europe and selected ROW territories.
![HD_block_scored5_edited.jpg](https://static.wixstatic.com/media/d29f85_c3fbfb28b25c4f4486255aed09473a0a~mv2_d_1812_2269_s_2.jpg/v1/fill/w_225,h_269,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/HD_block_scored5_edited.jpg)
Also Available
For Vets!
USE
DRY
Please click below to request further information on territories available for partnership, or to purchase TenaTac® in Europe:
![Innovation_WINNER_EM.png](https://static.wixstatic.com/media/d29f85_817649bca7c04ae9bbe84b85997a1de7~mv2.png/v1/fill/w_124,h_124,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Innovation_WINNER_EM.png)
This website is intended for healthcare professionals. TenaTac® is approved for use in Europe. TenaTac® is not approved for use in the USA.